Scleroderma Induced by Pembrolizumab: A Case Series

Naiara S. Barbosa, David A. Wetter, Carilyn N. Wieland, Niraj K. Shenoy, Svetomir N. Markovic, Uma Thanarajasingam

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

Original languageEnglish (US)
Pages (from-to)1158-1163
Number of pages6
JournalMayo Clinic Proceedings
Volume92
Issue number7
DOIs
StatePublished - Jul 2017
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Barbosa, N. S., Wetter, D. A., Wieland, C. N., Shenoy, N. K., Markovic, S. N., & Thanarajasingam, U. (2017). Scleroderma Induced by Pembrolizumab: A Case Series. Mayo Clinic Proceedings, 92(7), 1158-1163. https://doi.org/10.1016/j.mayocp.2017.03.016